Proof of leadership

Already live where
the market is going.

Not projections — production. The evidence a buying committee, a QA organization, or a regulator can check for themselves.

Pays où l’application ePI by PharmaLedger est opérationnelle

depuis 2023

Langues dans lesquelles l’application ePI fournit l’information approuvée

Partenaires fondateurs pharma, tech, académiques et patients

12 grands groupes pharma mondiaux

Standards ouverts unifiés : GS1 Digital Link, EU DPP, EPCIS 2.0

En production sur le réseau

Documented publicly

ISPE Pharma 4.0 Baseline Case Study No. 237

The ePI implementation journey — proof-of-concepts, TRL 7 assessment, 300+ validation users, and the April 2023 production launch — is published through ISPE, not just claimed here.

Read the case study →Regulated environments

Compliance you can inspect, not just cite

GxP-aware platform, 21 CFR Part 11 posture, tamper-evident audit trail — with the live platform status published openly in the Trust Center.

Open the Trust Center →Standards-led

Built on the standards the market is converging on

GS1 Digital Link, EPCIS 2.0, the EU Digital Product Passport, and ePI on HL7 FHIR — implemented in production, connected to your existing systems rather than replacing them.

Explore the standards →Enterprise qualification

Supplier-qualified for regulated pharma

Enterprise qualification proof is available for approved sales conversations.

Request a consultation →

See it yourself

Every major claim here links to a source: production evidence, association governance, status history, architecture reference, or a controlled document.

Bring your QA lead, your architect, or your regulatory team. 30 minutes, no procurement, no NDA.

Book a consultation →